
IAN READ, the chief executive of Pfizer, is not a man easily rebuffed. His attempt to woo AstraZeneca, a British drugs firm, included politesse—appearances before Parliament, web videos on Pfizer’s strategy—and, more importantly, a sweetened offer on May 18th worth around £70 billion ($120 billion). However, AstraZeneca’s board has rejected the bid and, as we went to press, it seemed dead in the water.
British politicians had cast Pfizer as a ruthless cost-cutter, out to gut British innovators. A rejected deal would therefore seem good for AstraZeneca and good for Britain. This reasoning, however, skirts two basic facts. First, AstraZeneca faces a rocky path on its own. The firm’s share price plunged by 12% on May 19th. The company will struggle to meet its goals of expanding revenue by 75% by 2023. More importantly, any relief at having saved a “national champion” ignores how modern pharmaceutical companies work.